Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 301-304

  Li, Cheng Guang ^a   Huang, Xin En ^a   Xu, Lin ^a   Li, Ying ^a   Lu, Yan Yan ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Lung cancer; NSCLC; Tumor associated material; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; OLIGOSACCHARIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864865020     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.301     Document Type: Article

References (33)

1. Basu PS, Majhi R, Batabyal SK (2003). Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin Biochem, 36, 373-6.
2. Dennis JW, Laferté S, Waghorne C, et al (1987). ß1-6 branching of asn-linked oligosaccharides is directly associated with metastasis. Science, 236, 582-5.
3. Deng H, Zhong BY, Peng GH, et al (2010). Application of Bo Xin SerumTumor Associated Material ( BXTM) in Malignant Tumor. Prac Prev Med, 17, 2493-5.
4. Diez M, Torres A, Maestro ML, et al (1996). Prediction of survival and recurrence by serum and cytosolic level sof CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 73, 1248-54.
5. Foa P, Fornier M, Miceli R, et al (1999). Tumour markers CEA, NSE, SCC, TPA and CYFRA21.1 in resectable non-small cell lungcancer. Anticancer Res, 19, 3613-8.
6. Gabius HJ (1988). Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew Chem, 27, 1267-76.
7. Gehan EA, Tefft MC (2000). Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. J Natl Cancer Inst, 92, 179-81.
8. Hakomori S (2000). Traveling for the glycosphingolipid path. Glycoconj J, 17, 627-47.
9. Hakomori S, Zhang Y (1997). Glycosphingolipid antigens and cancer therapy. Chem Biol, 4, 97-104.
10. Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60.
11. Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Medical Frontiers of China, 5, 80-1.
12. Kim YJ, Varki A (1997). Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J, 14, 569-76.
13. Kui Wong N, Easton RL, Panico M, et al (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619-34.
14. Liu ZM, et al (1986). Serum free proline and free hydroxyproline and its peptide-binding determination of hydroxyproline in the evaluation of bone tumors. Chinese J Laboratory Med, 9, 129-33 (Chinese).
15. MacDonald JS (1999). Carcinoembryonic antigen screening: Pros and cons. Sem Oncol, 26, 556-60.
16. Matsushita Y, Cleary KR, Ota DM, et al(1990).Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal-cancer metastases. Lab Invest,63, 780-91.
17. Meezan E, Wu HC, Black PH, et al (1969). Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry, 8, 2518-24.
18. Orntoft TF, Vestergaard EM (1999). Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis, 20, 362-71.
19. Pancino G, Osinaga E, Charpin C, et al (1991). Purification and characterization of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. Brit J Cancer, 63, 390-8.
20. Peracaula R, Tabarés G, Royle L, et al (2003). Altered glycosylation pattern allows the distinction between prostatespecifc antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-70.
21. Saussez S, Marchant H, Nagy N, et al (1998). Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer, 82, 252-60.
22. Sell S (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path, 21, 1003-19.
23. Serum tumor associated material (TAM) testing kit, QINGDAO BO-XING Biotechnology Co., Ltd. http://www.cqtrueway. com.
24. Shriver Z, Raguram S, Sasisekharan R (2004). Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Disc, 3, 863-73.
25. Taylor-Papadimitriou J, Epenetos AA (1994). Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech, 12, 227-33.
26. Turner GA (1992). N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin Chim Acta, 208, 149-71.
27. Vinolas N, GalanMC, Casas F, et al (1998). Tumor markers inresponse monitoring and prognosis of non small cell lungcancer. Preliminaryreport Anticancer Res, 18, 631-4.
28. Wu HX, et al (1983). Encyclopedia of Chinese Medical Oncology. Shanghai Science and Technology Press, 63 (Chinese).
29. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
30. Zhang S, Cordon-Cardo C, Zhang HS, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I.Focus on gangliosides. Int J Cancer, 73, 42-9.
31. Zhang S, Zhang HS, Cordon-Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer, 73, 50-6.
32. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
33. Zou X, Zhang XS, Sui L, et al (2004). Role of tulnor associated material (BXTM) in early diagnosing malignant tumor. Qilu J Med Laboratory Sci, 15, 4-6.